A review of monoclonal antibody therapies in lymphoma.

@article{Teo2016ARO,
  title={A review of monoclonal antibody therapies in lymphoma.},
  author={Esmeralda Chi-yuan Teo and Yveline Chew and Colin D Phipps},
  journal={Critical reviews in oncology/hematology},
  year={2016},
  volume={97},
  pages={72-84}
}
Monoclonal antibodies (moAb) represent a novel way of delivering therapy through specific target antigens expressed on lymphoma cells and minimizes the collateral damage that is common with conventional chemotherapy. The paradigm of this approach is the targeting of CD20 by rituximab. Since its FDA approval in 1997, rituximab has become the standard of care in almost every line of therapy in most B-cell lymphomas. This review will briefly highlight some of the key rituximab trials while looking… CONTINUE READING